Efficacy of 1% XXXX cream in comparison with 0.75% @entity868 gel for the treatment of @entity6509 .

@entity1 @entity8974 @entity868 @entity8721 @entity8304 @entity111 @entity4974 @entity6509
BACKGROUND: Topical antifungals comprising @entity8304 derivatives have been used for the treatment of @entity6509 previously, owing to their anti-inflammatory activities. @entity8974 , an antifungal agent belongs to @entity4974 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity8974 has been used systemically for @entity6509 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity8974 1% cream for the treatment of mild and moderate @entity6509 , and compared the results with those of 0.75% @entity868 gel. @entity1 /METHODS: Forty @entity1 , 30 females and 10 males, with @entity6509 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity1 were instructed to apply 1% @entity8974 cream, whereas others @entity1 of the study population were instructed to use 0.75% @entity868 gel. A total of 32 @entity1 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity8721 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity8974 group, although the percentage was 45% in @entity868 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity111 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity8974 cream is an effective and safe treatment for @entity6509 , and can be an option for @entity1 who cannot tolerate other modalities.
